GRAIL is trading 6.2% up at $75.30, significantly outperforming its August 18 close of $70.89 amid biotech-sector strength following positive Moderna cancer-vaccine trial results.
- No new company-specific announcement dated August 19, 2026 was identified.
- Biotech is rising 3.73% after the trial results.
- GRAIL’s September 23 FDA advisory review remains a supportive background catalyst; it was announced August 7.